| 吉西他滨联合铂类药物治疗晚期胰腺癌的疗效观察 |
| |
| 引用本文： | 卢凯华,仇金荣,黄普文,穆庆霞,王榕生,朱陵君,束永前,刘宝瑞.吉西他滨联合铂类药物治疗晚期胰腺癌的疗效观察[J].中国基层医药,2004,11(10):1153-1154. |
| |
| 作者姓名： | 卢凯华 仇金荣 黄普文 穆庆霞 王榕生 朱陵君 束永前 刘宝瑞 |
| |
| 作者单位： | 210093,江苏,南京,南京大学医学院研究生班,江苏省人民医院肿瘤中心 |
| |
| 摘 要： | 目的 观察吉西他滨(健择)联合顺铂/草酸铂(GP/GEM-OX方案)治疗晚期不能手术或手术后复发的胰腺癌患者的疗效与不良反应。方法 28例患者分别给予GP或GEM-OX方案2～13周期。按WHO标准评定疗效和不良反应。结果 26例可评价疗效，无一例完全缓解(CR，0％)，部分缓解(PR)7例(26．9％)，稳定(SD)10例(38．5％)，进展(PD)9例(34．6％)。可评价临床受益反应(CBR)27例，有效率为70．4％(19／27)。中位疾病进展时间为4．2个月，中位生存时间为9．3个月。结论 健择联合顺铂/草酸铂是治疗晚期胰腺癌患者的安全有效方案，并能较好改善疾病相关症状，毒副反应可以耐受。
|
| 关 键 词： | 治疗 联合 吉西他滨 晚期胰腺癌 患者 铂类药物 健择 结论 标准评定 GEM |
| 修稿时间： | 2004年7月5日 |
A clinical studay of gemzar plus cisplatin or oxaliplatin in the treatment of advanced pancreatic cancer |
| |
| LU Kai hua,QIU Jin rong,HUANG Pu wen,et al..A clinical studay of gemzar plus cisplatin or oxaliplatin in the treatment of advanced pancreatic cancer[J].Chinese Journal of Primary Medicine and Pharmacy,2004,11(10):1153-1154. |
| |
| Authors: | LU Kai hua QIU Jin rong HUANG Pu wen |
| |
| Institution: | LU Kai hua,QIU Jin rong,HUANG Pu wen,et al.Department of Oncology,Jiangsu Province Hospital,Nanjing,210029,China |
| |
| Abstract: | Objective To observe the efficacy and toxicity of gemzar plus cisplatin or oxaliplatin for advanced pancreatic cancer.Methods The clinical data of 28 cases with advanced pancreatic cancer treated with GP/GEM OX regimen were analyzed.Results 26 patients were available for objective response and 27 for CBR evaluation.CR 0(0%),PR 7(26.9%),SD 10(38.5%),PD 9(34.6%).Positive CBR was 19/27(70.4%).The median time of disease progression was 4.2 months with median survivals of 9.3 months.Conclusion Gemzar plus cisplatin or oxaliplatin is an effective and safe chemotherapeutic protocol for the treatment of advanced pancreatic cancer.It also significantly improvs the life quality of patients. |
| |
| Keywords: | Pancreatic neoplasms Gemcitabine Efficacy Toxicity |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
